News | Left Atrial Appendage (LAA) Occluders | October 19, 2023

Conformal Medical to Present One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Study at TCT 2023

The CLAAS System to be highlighted daily at TCT, including a live case presentation by Dr. Shephal Doshi

The CLAAS System to be highlighted daily at TCT, including a live case presentation by Dr. Shephal Doshi

Conformal Medical's CLAAS Implant (PRNewsfoto/Conformal Medical, Inc.) 


October 19, 2023 — Conformal Medical, Inc. announced today the one-year results from the company's CONFORMAL Early Feasibility Study (EFS) will be presented during the 2023 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, CA. Dr. William Gray, System Chief, Cardiovascular Diseases at Main Line Health and professor at Lankenau Institute for Medical Research will present, "Conformal CLAAS LAAO Device EFS 1-Year TEE Follow Up" during a moderated abstract session. 

"I look forward to presenting the much anticipated one-year TEE follow up data from our initial clinical experience," stated Dr. Gray. "LAAO has emerged as an important alternative to anticoagulants for patients with atrial fibrillation who are at an increased risk of stroke and the CLAAS device has several compelling design advantages that may prove helpful in treating these patients." 

The multi-center, single-arm feasibility study investigated the safety and performance of the CLAAS System and included TEE performed intra-procedurally, at 45 days and one year following implantation. The novel implant is designed to seal the LAA in patients with non-valvular atrial fibrillation (Afib) to reduce the risk of stroke without the need for anticoagulants. Featuring a proprietary foam-based architecture, the CLAAS implant addresses a wide spectrum of LAA anatomies with only two sizes, while simplifying device delivery and streamlining the procedure. 

"We are extremely pleased to have the one-year Conformal EFS data presented at this year's TCT conference," commented James Reinstein, CEO of Conformal Medical. "We look forward to sharing the positive findings of the CLAAS System and continuing to build a robust body of evidence supporting this next-generation technology for patients suffering from atrial fibrillation and at an increased risk of stroke." 

Conformal Medical is currently enrolling patients in its CONFORM Pivotal Trial to support U.S. commercialization. 

Conformal Medical at Transcatheter Cardiovascular Therapeutics (TCT) 2023 

Tuesday, October 24th - Dr. William Gray will present, "Conformal CLAAS LAAO Device EFS 1-Year TEE Follow Up" during the Imaging in LAA Occlusion Procedures moderated abstract session at 10am PT in Hall A South. 

Wednesday, October 25th - Conformal Medical to host a breakfast symposium, "CLAAS Act: Conformal Medical Overview and CONFORM Trial Update" at 6:30am PT in Presentation Theater 1. 

Thursday, October 26th - Dr. Shephal Doshi, Executive Director, Heart & Vascular Institute, Providence St. John's Health Center & Cardiac Electrophysiology at the Pacific Heart Institute, will perform a live case presentation with the CLAAS System at 11:45am in the Structural Theater, Hall F North. 

For more information: https://conformalmedical.com/ 

Find more TCT23 conference coverage here


Related Content

News | TCT

Oct. 11, 2024 – As the pace of change accelerates in healthcare, the most pressing questions in cardiovascular medicine ...

Home October 16, 2024
Home
News | TCT

November 9, 2023 — Medinbox, a global provider of video integrated collaboration systems for interventional rooms and ...

Home November 09, 2023
Home
News | TCT

October 30, 2023 — Shockwave Medical, Inc., which develops technologies for the treatment of cardiovascular disease, has ...

Home October 30, 2023
Home
News | TCT

October 26, 2023 — The Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgeons have issued ...

Home October 26, 2023
Home
News | TCT

October 26, 2023 — A new study presented at TCT 2023 revealed inequities in access to mechanical circulatory support in ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Elixir Medical, developer of novel cardiovascular technologies, announced positive six-month clinical ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Medtronic plc, a global leader in healthcare technology, announced four-year results from the Evolut ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Information on a new double lumen catheter was presented by Nabil Dib, MD, MSc, FACC, FESC, during ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — For its novel multi-lumen stent system for interventional adjustment of pulmonary blood flow in ...

Home October 25, 2023
Home
Feature | TCT | By Melinda Taschetta-Millane

Innovation. Connection. Inspiration. The Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference, the ...

Home October 20, 2023
Home
Subscribe Now